Group 1 - The A-share market opened lower and experienced significant adjustments, while the healthcare sector showed resilience with major stocks like WuXi AppTec rising over 1% and Aier Eye Hospital increasing by over 2% [1] - The largest healthcare ETF (512170) has seen a net subscription of 2.688 billion yuan over the past 13 days, indicating strong investor interest [1] - The pharmaceutical sector showed mixed performance, with innovative drug concepts mostly declining, while traditional Chinese medicine stocks like Darentang rose over 4% [3] Group 2 - The National Medical Products Administration announced support for the biomanufacturing industry during the 14th Five-Year Plan, aiming to shift the pharmaceutical industry towards systematic innovation and quality growth [5] - Analysts are optimistic about the Chinese medicine sector's recovery driven by policy support, cost improvements, and expected adjustments in the essential drug catalog [5] - Zhongtai Securities is bullish on the raw material drug sector, anticipating price improvements after several years of price declines, with most API product prices at historical lows [5] Group 3 - The largest healthcare ETF (512170) has over 50% weight in medical devices and more than 25% in CXO, covering 12 AI medical and brain-computer interface concept stocks [5] - The only pharmaceutical ETF (562050) has over 60% allocation in innovative drugs while also considering high-dividend Chinese medicine stocks [5] - As of February 3, 2026, the healthcare ETF has a total scale of 27.5 billion yuan, making it the largest in the market [6]
医药韧性凸显!中药龙头领涨,场内唯一药ETF逆市飘红!规模最大医疗ETF(512170)吸金26亿后延续高频溢价
Xin Lang Ji Jin·2026-02-05 03:27